Morpholines

• 

  Subject Areas on Research

  • A comparison of the combination of aprepitant and dexamethasone versus the combination of ondansetron and dexamethasone for the prevention of postoperative nausea and vomiting in patients undergoing craniotomy. 
  • A genomic approach to identify molecular pathways associated with chemotherapy resistance. 
  • A new era in secondary prevention after acute coronary syndrome. 
  • A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. 
  • A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. 
  • Activation of Akt/PDK signaling in macrophages upon binding of receptor-recognized forms of alpha2-macroglobulin to its cellular receptor: effect of silencing the CREB gene. 
  • Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012. 
  • An animal model of MYC-driven medulloblastoma. 
  • An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). 
  • Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers. 
  • Anticoagulation in atrial fibrillation. 
  • Antiemetics: American Society of Clinical Oncology clinical practice guideline update. 
  • Aprepitant for the Treatment of Chronic Refractory Pruritus. 
  • Aprepitant: a novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma. 
  • Assays for measuring rivaroxaban: their suitability and limitations. 
  • Atrial fibrillation, valvular heart disease, and use of target-specific oral anticoagulants for stroke prevention. 
  • Bone Marrow Mesenchymal Stem Cell Transplantation Increases GAP-43 Expression via ERK1/2 and PI3K/Akt Pathways in Intracerebral Hemorrhage. 
  • CD19 amplification of B lymphocyte Ca2+ responses: a role for Lyn sequestration in extinguishing negative regulation. 
  • Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin? 
  • Characterization of the antiabsence effects of SCH 50911, a GABA-B receptor antagonist, in the lethargic mouse, gamma-hydroxybutyrate, and pentylenetetrazole models. 
  • Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. 
  • Clinical experience with substance P receptor (NK1) antagonists in depression. 
  • Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. 
  • Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. 
  • Conformation guides molecular efficacy in docking screens of activated β-2 adrenergic G protein coupled receptor. 
  • Coordinate regulation of forskolin-induced cellular proliferation in macrophages by protein kinase A/cAMP-response element-binding protein (CREB) and Epac1-Rap1 signaling: effects of silencing CREB gene expression on Akt activation. 
  • Curative Treatment of Severe Gram-Negative Bacterial Infections by a New Class of Antibiotics Targeting LpxC. 
  • Cytosolic delivery of macromolecules 4. Head group-dependent membrane permeabilization by pH-sensitive detergents. 
  • Cytosolic delivery of macromolecules. II. Mechanistic studies with pH-sensitive morpholine lipids. 
  • DVT: a new era in anticoagulant therapy. 
  • Delivery of phosphorodiamidate morpholino antisense oligomers in cancer cells. 
  • Differential regulation of MeCP2 phosphorylation in the CNS by dopamine and serotonin. 
  • Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). 
  • Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons. 
  • Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. 
  • Effects of U-37883A, a vascular selective KATP+ channel antagonist, in the pulmonary and hindlimb circulation. 
  • Effects of neurotoxic destruction of descending noradrenergic pathways on cannabinoid antinociception in models of acute and tonic nociception. 
  • Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT(2A) receptor antagonism on the firing activity of norepinephrine neurons. 
  • Effects of the selective norepinephrine reuptake inhibitor reboxetine on norepinephrine and serotonin transmission in the rat hippocampus. 
  • Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). 
  • Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. 
  • Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. 
  • Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. 
  • Emergence of anxiety-like behaviours in depressive-like Cpe(fat/fat) mice. 
  • End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. 
  • Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. 
  • FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function. 
  • Factor Xa induces tissue factor expression in endothelial cells by P44/42 MAPK and NF-κB-dependent pathways. 
  • Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). 
  • Growth-dependent regulation of cellular ceramides in human T-cells. 
  • Haptotactic gradients for directed cell migration: stimulation and inhibition using soluble factors. 
  • Hedgehog signaling activates a positive feedback mechanism involving insulin-like growth factors to induce osteoblast differentiation. 
  • High-frequency organization and synchrony of activity in the purkinje cell layer of the cerebellum. 
  • Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. 
  • Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. 
  • In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. 
  • Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells. 
  • Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. 
  • Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. 
  • Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. 
  • Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer. 
  • Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. 
  • Laser-scanning velocimetry: a confocal microscopy method for quantitative measurement of cardiovascular performance in zebrafish embryos and larvae. 
  • Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. 
  • Managing new oral anticoagulants in the perioperative and intensive care unit setting. 
  • Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. 
  • Mechanistic insights into the cytotoxicity and genotoxicity induced by glycidamide in human mammary cells. 
  • Motor cortex excitability after vagus nerve stimulation in major depression. 
  • Nephrocystin-3 is required for ciliary function in zebrafish embryos. 
  • Novel oral anticoagulants in gastroenterology practice. 
  • Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. 
  • Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. 
  • Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). 
  • Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). 
  • Oxidant-mediated Akt activation in human RPE cells. 
  • P38MAP kinase, but not phosphoinositol-3 kinase, signal downstream of glutamine-mediated fibronectin-integrin signaling after intestinal injury. 
  • PAK1 mediates resistance to PI3K inhibition in lymphomas. 
  • PI3K inhibitors block skeletogenesis but not patterning in sea urchin embryos. 
  • PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression. 
  • Perioperative management of patients on chronic antithrombotic therapy. 
  • Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. 
  • Pharmacokinetic-pharmacodynamic modeling of apratastat: a population-based approach. 
  • Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists. 
  • Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. 
  • Phosphatidylinositol 3-kinase activates ERK in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization. 
  • Phosphatidylinositol 3-kinase is an early intermediate in the G beta gamma-mediated mitogen-activated protein kinase signaling pathway. 
  • Pilot study of aprepitant for prevention of post-ERCP pancreatitis in high risk patients: a phase II randomized, double-blind placebo controlled trial. 
  • Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor. 
  • Point-of-Care Warfarin Monitoring in the ROCKET AF Trial. 
  • Point-of-Care Warfarin Monitoring in the ROCKET AF Trial. 
  • Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF. 
  • Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. 
  • Quantitative trait locus and computational mapping identifies Kcnj9 (GIRK3) as a candidate gene affecting analgesia from multiple drug classes. 
  • RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. 
  • Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. 
  • Reciprocal control of Forkhead box O 3a and c-Myc via the phosphatidylinositol 3-kinase pathway coordinately regulates p27Kip1 levels. 
  • Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. 
  • Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. 
  • Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model. 
  • Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation". 
  • Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts". 
  • Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. 
  • Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. 
  • Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. 
  • Rivaroxaban, an oral direct factor Xa inhibitor. 
  • Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. 
  • Role of K+ATP channels and EDRF in reactive hyperemia in the hindquarters vascular bed of cats. 
  • Role of Transient Receptor Potential Vanilloid 4 in Neutrophil Activation and Acute Lung Injury. 
  • Single Cell Chemical Cytometry of Akt Activity in Rheumatoid Arthritis and Normal Fibroblast-like Synoviocytes in Response to Tumor Necrosis Factor α. 
  • Single-cell microarray enables high-throughput evaluation of DNA double-strand breaks and DNA repair inhibitors. 
  • Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery. 
  • Sphingolipids--the enigmatic lipid class: biochemistry, physiology, and pathophysiology. 
  • Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding. 
  • Sustenance of endothelial cell stability in septic mice through appropriate activation of transient receptor potential vanilloid-4. 
  • Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity. 
  • TRPV4 channel contributes to serotonin-induced pulmonary vasoconstriction and the enhanced vascular reactivity in chronic hypoxic pulmonary hypertension. 
  • TRPV4 is necessary for trigeminal irritant pain and functions as a cellular formalin receptor. 
  • The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. 
  • The importance of VTE prevention after orthopaedic surgery. 
  • The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials. 
  • The synthetic cannabinoid WIN 55212-2 differentially modulates thigmotaxis but not spatial learning in adolescent and adult animals. 
  • Upregulation of mTORC2 activation by the selective agonist of EPAC, 8-CPT-2Me-cAMP, in prostate cancer cells: assembly of a multiprotein signaling complex. 
  • Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. 
  • Urinary bladder organ hypertrophy is partially regulated by Akt1-mediated protein synthesis pathway. 
  • Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. 
  • VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. 
  • Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. 
  • Vascular smooth muscle cell migration induced by domains of thrombospondin-1 is differentially regulated. 
  • X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. 
  • c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model. 
  • mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. 
• 

  Keywords of People

  • Buckley, Anne Frances, Assistant Professor of Pathology, Pathology
  • Levy, Jerrold Henry, Professor of Anesthesiology, Anesthesiology, Cardiothoracic
  • McLendon, Roger Edwin, Professor of Pathology, Pathology